文献速递免疫规划传染病防控与疫情报告

重组奥密克戎BA.4/5-Delta新冠疫苗ZF2202-A在中国成人中的免疫原性与安全性

Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults.
PubMed 文献 · Vaccine · 2024-05-03

一项随机双盲活性对照试验纳入450名≥18岁、已完成基础或加强接种超过6个月的中国成人,比较ZF2202-A与ZF2001各一剂。接种后14天,ZF2022-A组对奥密克戎BA.4/5、BF.7、XBB.1的血清转化率分别为67.7%、58.6%、62.6%,中和抗体GMT分别为350.2、491.8、49.5,两组主要不良反应为接种部位疼痛、瘙痒、疲乏和无力。

要点

  • ZF2202-A组接种后14天对奥密克戎BA.4/5、BF.7、XBB.1的血清转化率分别为67.7%、58.6%、62.6%。
  • ZF2202-A组接种后14天对上述三株的中和抗体GMT分别为350.2、491.8、49.5。
  • 两组主要不良反应均为接种部位疼痛、瘙痒、疲乏和无力。

核心结论

  • 新型二价疫苗ZF2202-A作为既往接种过新冠疫苗成人的加强剂,对奥密克戎变异株显示出满意的免疫原性和安全性。

研究设计与样本

  • 随机、双盲、活性对照试验,纳入450名≥18岁、已完成新冠疫苗基础或加强接种超过6个月的中国成人。
  • 研究组和对照组分别接种一剂ZF2202-A和ZF2001,各组内设立免疫原性亚组。

主要发现

  • 接种后14天,ZF2022-A组对奥密克戎BA.4/5、BF.7、XBB.1的血清转化率分别为67.7%、58.6%、62.6%。
  • 接种后14天,ZF2022-A组对奥密克戎BA.4/5、BF.7、XBB.1的中和抗体GMT分别为350.2、491.8、49.5。
  • ZF2022-A组和ZF2001组的主要不良反应均为接种部位疼痛、瘙痒、疲乏和无力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Recombinant Omicron BA.4/5-Delta COVID-19 Vaccine (ZF2202-A) is primarily designed for the Delta and Omicron BA.4/5 variants. Our objective was to assess the safety and immunogenicity of ZF2202-A in Chinese adults. METHODS: A total of 450 participants aged ≥ 18 years, who had completed primary or booster vaccination with a COVID-19 vaccine more than 6 months prior, were enrolled in this randomized, double-blind, active-controlled trial. Participants in the study and control groups were administered one dose of ZF2202-A and ZF2001, respectively. Immunogenicity subgroups were established in each group. RESULTS: At 14 days after vaccination, the seroconversion rates of Omicron BA.4/5, BF.7, and XBB.1 in the ZF2022-A group were 67.7 %, 58.6 %, and 62.6 %, with geometric mean titers (GMTs) of neutralizing antibodies at 350.2, 491.8, and 49.5, respectively. The main adverse reactions (ARs) were vaccination site pain, pruritus, fatigue, and asthenia in both the ZF2022-A group and ZF2001 group. CONCLUSIONS: The novel bivalent vaccine ZF2202-A demonstrated satisfactory immunogenicity and safety against Omicron variants as booster dose in adults with prior vaccination of COVID-19 vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hu H, Ma F, Gong L, et al. Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults. Vaccine. 2024. PMID: 38704251. doi:10.1016/j.vaccine.2024.04.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。